SEC For	rm 4																	
FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549														1		
		Washington, D.C. 20549												OMB APPROVAL				
Check this box if no longer subject to Section 16. Form 4 or Form 5					INT	NT OF CHANGES IN BENEFICIAL OWNERSHIP										OMB Number: 3235-0287 Estimated average burden		
obligat	ed pu	pursuant to Section 16(a) of the Securities Exchange Act of 1934											sponse:	0.5				
					0	or Sect	ion 30(h)	of th	e Investment	Company Ad	ct of 1940							
1. Name and Address of Reporting Person*													5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
GHALIE RICHARD G												Director 10% Owner X Officer (give title Other (specify balave)						
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year)								A below) below) Chief Medical Officer					
C/O ME	I PHARMA				05/03/2021								Chief Medical Officer					
11455 EL CAMINO REAL, SUITE 250														dividual or 1	oint/Croun	Filing	(Chaol: Ap	
(Street)				4.									6. Individual or Joint/Group Filing (Check Applicable Line)					
SAN DIEGO CA 92130													X Form filed by One Reporting Person Form filed by More than One Reporting					
														Person				
(City) (State) (Zip)																		
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Da				2. Trans Date			2A. Deemed Execution Date			ion Dispos	ities Acquired (A) d Of (D) (Instr. 3, 4		and Securitie		s	Form: Direct		7. Nature of Indirect Beneficial Ownership (Instr. 4)
			(Month/				if any (Month/Day/Yea		ar) Code (Ins	str. 5)				Beneficia Owned Fo Reported	ollowing (I) (		str. 4)	
								Code V	Amoun	t (A) c (D)	(A) or (D) Price		Transaction(s) (Instr. 3 and 4)				(1150.4)	
<u> </u>			Table II -	Deriva	tive	Sec	urities	Aco	uired, Dis	sposed o	f. or Ber	eficia	llv (	Owned				
									s, options									
1. Title of Derivative	2. Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D	ate, T	4. Transacti				Expiration D	Exercisable and 7. Title and Amo on Date of Securities			nt	8. Price of Derivative	9. Numbe derivative	•	10. Ownership	
Security (Instr. 3)	or Exercise Price of Derivative		if any (Month/Day			(Instr. Deriv Secu		ies	(Month/Day/	(Month/Day/Year)		Underlying Derivative Security (Instr. 3 and 4)		Security (Instr. 5)	Securities Beneficially Owned		Form: Direct (D) or Indirect	Beneficial Ownership
	Security						Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)				(insu: 5 and 4)				Following Reported		(I) (Instr. 4)	(Instr. 4)
															Transaction( (Instr. 4)			
											Amour		nt					
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Number of Sha						
Stock																		
Option (Right to	\$3.55	05/03/2021			Α		75,000		(1)	05/03/2031	Common Stock	75,0	00	\$ <mark>0</mark>	75,00	0	D	
Buy) Stock								$\vdash$					_					
Option (Right to	\$1.21								(2)	03/07/2026	Common Stock	130,0	000		130,00	00	D	
Buy)							<u> </u>				<u> </u>		_					<u> </u>
Stock Option	\$1.38								(2)	07/14/2026	Common	25,0	00		155,00	00	D	
(Right to Buy)											Stock							
Stock Option											Common							
(Right to Buy)	\$2.88								(3)	07/07/2027	Stock	65,0	00		220,00	00	D	
Stock								┢										
Option (Right to	\$4.28								(4)	07/12/2028	Common Stock	130,0	000		350,00	00	D	
Buy)							<u> </u>					<u> </u>	_					
Stock Option (Right to	\$2.52								(5)	07/01/2029	Common Stock	150,0	000		500,00	00	D	
(Right to Buy)											SIUCK							
Stock Option	\$3.49								(6)	07/02/2030	Common	150,0			650,00	00	D	
(Right to Buy)	φ <b>3.4</b> 9									0770272030	Stock	1.50,0	00		050,00	<i>.</i> 0		
		1	1			1	1	1		1	1	1			1			1

Explanation of Responses:

1. 1/4th of shares vest one-year from 5/03/2021, with the remaining balance of shares vesting in 36 equal amounts over three years.

2. All options are currently exercisable.

3. 1/4th of shares vest one-year from July 7, 2017, with the remaining balance of shares vesting in 36 equal amounts over three years.

4. 1/4th of shares vest one-year from July 12, 2018, with the remaining balance of shares vesting in 36 equal amounts over three years.

5. 1/4th of shares vest one-year from July 1, 2019, with the remaining balance of shares vesting in 36 equal amounts over three years.

6. 1/4th of shares vest one-year from July 2, 2020, with the remaining balance of shares vesting in 36 equal amounts over three years.

/s/ Richard Ghalie MD

\*\* Signature of Reporting Person Date

05/05/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $\ast$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.